The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
Open accessAbstract
// Anil Belur Nagaraj 1 , Peronne Joseph 1 , Olga Kovalenko 1 , Sareena Singh 2 , Amy Armstrong 2 , Raymond Redline 3 , Kimberly Resnick 2 , Kristine Zanotti 2 , Steven Waggoner 2 and Analisa DiFeo 1 1 Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA 2 Department of Gynecology, Division of Gynecological Oncology, University Hospital Case Medical Center, Cleveland, OH, USA 3 Department of Pathology, University Hospital Case Medical Center, Cleveland, OH, USA Correspondence to: Analisa DiFeo, email: // Keywords : patient derived xenograft, platinum resistance, tumor spheres, cancer initiating cells, β-catenin Received : April 23, 2015 Accepted : June 01, 2015 Published : June 29, 2015 Abstract Resistance to platinum-based chemotherapy is the major barrier to treating epithelial ovarian cancer. To improve patient outcomes, it is critical to identify the underlying mechanisms that promote platinum resistance. Emerging evidence supports the concept that platinum-based therapies are able to eliminate the bulk of differentiated cancer cells, but are unable to eliminate cancer initiating cells (CIC). To date, the relevant pathways that regulate ovarian CICs remain elusive. Several correlative studies have shown that Wnt/β-catenin pathway activation is associated with poor outcomes in patients with high-grade serous ovarian cancer (HGSOC). However, the functional relevance of these findings remain to be delineated. We have uncovered that Wnt/β-catenin pathway activation is a critical driver of HGSOC chemotherapy resistance, and targeted inhibition of this pathway, which eliminates CICs, represents a novel and effective treatment for chemoresistant HGSOC. Here we show that Wnt/β-catenin signaling is activated in ovarian CICs, and targeted inhibition of β-catenin potently sensitized cells to cisplatin and decreased CIC tumor sphere formation. Furthermore, the Wnt/β-catenin specific inhibitor iCG-001 potently sensitized cells to cisplatin and decreased stem-cell frequency in platinum resistant cells. Taken together, our data is the first report providing evidence that the Wnt/β-catenin signaling pathway maintains stem-like properties and drug resistance of primary HGSOC PDX derived platinum resistant models, and therapeutic targeting of this pathway with iCG-001/PRI-724, which has been shown to be well tolerated in Phase I trials, may be an effective treatment option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt signaling mediates regional specification in the vertebrate face
Brugmann, S. A., Goodnough, L. H., Gregorieff, A., Leucht, P., ten Berge, D., Fuerer, C., Clevers, H., Nusse, R., & Helms, J. A. (2007) · Development · doi:10.1242/dev.005132 · Cited by 213
Evolution of platinum resistance in high-grade serous ovarian cancer
Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y., Conner, M., Hidalgo, B., Alvarez, R. D., Landen, C. N., Straughn, J. M., & Buchsbaum, D. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.005 · Cited by 161
Cited by
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Krishnamurthy, N., & Kurzrock, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Targeting FAK in anticancer combination therapies
Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 384
Cancer stem cells: The root of tumor recurrence and metastases
Peitzsch, C., Tyutyunnykova, A., Pantel, K., & Dubrovska, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.011 · Cited by 372
The role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2017) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 300
Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
Devarakonda, S., Rotolo, F., Tsao, M.-S., Lanc, I., Brambilla, E., Masood, A., Olaussen, K. A., Fulton, R., Sakashita, S., McLeer-Florin, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1963 · Cited by 272
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife · doi:10.7554/elife.47327 · Cited by 145
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05626-2 · Cited by 93
Cell signaling and cancer: a mechanistic insight into drug resistance
Panda, M., & Biswal, B. K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04958-6 · Cited by 89
Metadata
- Authors
- Nagaraj, A. B., Joseph, P., Kovalenko, O., Singh, S., Armstrong, A., Redline, R., Resnick, K., Zanotti, K., Waggoner, S., & DiFeo, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-06-29
- Volume
- 6
- Issue
- 27
- Pages
- 23720-23734
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1695398347
- Cited by
- 195
- References
- 3
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.